CYTK Cytokinetics Incorporated

Cytokinetics Announces Publication of Manuscript Detailing Baseline Characteristics of GALACTIC-HF in European Journal of Heart Failure

Cytokinetics Announces Publication of Manuscript Detailing Baseline Characteristics of GALACTIC-HF in European Journal of Heart Failure
EN
02/10/2020

Underlying

CYTKCytokinetics Incorporated

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cytokinetics Incorporated

 PRESS RELEASE
Free
CYTK Cytokinetics I...

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 563...

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 15, 2025 it granted stock options to purchase an aggregate of 83,583 shares of common stock and 56,334 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 11 employees, whose employment commenced in May and June, 2025, as a material inducement to their employment. The RSUs will vest over 3 years, with 40% of the RSUs vesting on the first a...

June 17, 2025 1 EN
 PRESS RELEASE
Free
CYTK Cytokinetics I...

Cytokinetics Announces Call For Proposals For Annual Corporate Giving ...

Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program Program to Provide Donations to Non-Profit Organizations Aligned with Corporate Values Deadline for Applications is August 4th, 2025 SOUTH SAN FRANCISCO, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for its annual Cytokinetics Corporate Giving Program. The program provides charitable donations to eligible non-profit organizations in the United States to support equitable healthcare initiatives for cardiovascular disease, diversity in ...

June 10, 2025 1 EN
Free Trial
CYTK Cytokinetics I...

Cytokinetics Inc: 2 directors

Two Directors at Cytokinetics Inc sold 12,295 shares at between 32.040USD and 32.100USD. The significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the...

CYTK CYTOKINETICS INCORPORATED
06/05/25 June 5, 2025 1 EN
 PRESS RELEASE
Free
CYTK Cytokinetics I...

Cytokinetics to Participate in the Jefferies Global Healthcare Confere...

Cytokinetics to Participate in the Jefferies Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company’s management team are scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 9:20 AM Eastern Time at the New York Marriott Marquis Hotel in New York, NY. Interested parties may access the live webcast of the fireside chat by visiting the Investors & Media section of the Cytokinetics website at . The webcas...

May 29, 2025 1 EN
 PRESS RELEASE
Free
CYTK Cytokinetics I...

Cytokinetics Presents Additional Data Related to Aficamten at the Euro...

Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress  Two New Analyses from SEQUOIA-HCM on Effect of Aficamten Between Patientswith Mild and Moderate-to-Severe Symptoms, and Across Geographic Regions HEOR Analyses of Real-World Data Reveal Disparities in Outcomes In Females and Older Patients with Non-Obstructive HCM SOUTH SAN FRANCISCO, Calif., May 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data arising from two analyses from SEQUOIA-HCM, (Safety, Efficacy...

May 18, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch